Want to see PL:RVU full AI Analyst Report?
Top Page
Ryvu Therapeutics SA
(RVU)
Select Model
Select Model
Rating:37Underperform
Price Target:
zł27.00
▼(-2.35% Downside)
Action:N/A
Date:09/16/25
The stock score is driven by the company’s persistently weak financial performance—recurring net and cash flow losses, negative ROE, and poor valuation. Revenue growth and high gross margin are positives but are not sufficient to offset sustainability concerns given deep losses and high cash burn. The lack of technical or valuation support, and absence of dividend or positive earnings guidance, anchor the score at the minimum allowed.
Positive Factors
Revenue Growth
The company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.
Negative Factors
Profitability Challenges
Ongoing profitability issues highlight difficulties in converting revenue into net income, which could hinder long-term financial health and investment in growth opportunities.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The company's strong revenue growth rate indicates expanding operations and potential market capture, which is crucial for long-term sustainability in the competitive biotech industry.
Read all positive factors
Ryvu Therapeutics SA (RVU) vs. SPDR S&P 500 ETF (SPY)
Market Cap
zł427.72M
Dividend YieldN/A
Average Volume (3M)26.70K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth-15.04%
EPS Growth24.48%
CountryPL
Employees228
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.91
Shares Outstanding23,120,148
10 Day Avg. Volume24,770
30 Day Avg. Volume26,695
Financial Highlights & Ratios
PEG Ratio0.68
Price to Book (P/B)11.64
Price to Sales (P/S)10.06
P/FCF Ratio-5.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-2.18
Revenue Forecast (FY)zł119.05M
Ryvu Therapeutics SA Business Overview & Revenue Model
Company Description
Ryvu Therapeutics S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing novel small molecule treatments for oncology. Their primary experimental drug, RVU120, functions as a CDK8 kinase inhibitor and shows promise ...
How the Company Makes Money
Ryvu Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company earns money through various streams including milestone payments from partnerships with larger pharmaceutical companies...
Ryvu Therapeutics SA Financial Statement Overview
Summary
Income Statement
27
Negative
Balance Sheet
39
Negative
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.27M | 62.25M | 77.97M | 46.86M | 38.80M | 11.19M |
| Gross Profit | -29.73M | -117.03M | 58.39M | 29.31M | 21.40M | -2.54M |
| EBITDA | -85.94M | -112.71M | -96.83M | -81.04M | -65.21M | -65.96M |
| Net Income | -88.60M | -101.23M | -111.44M | -92.11M | -83.78M | -79.08M |
Balance Sheet | ||||||
| Total Assets | 200.96M | 224.44M | 378.78M | 403.20M | 474.98M | 228.81M |
| Cash, Cash Equivalents and Short-Term Investments | 79.05M | 107.68M | 225.40M | 233.67M | 102.44M | 88.23M |
| Total Debt | 73.64M | 71.72M | 75.51M | 906.00K | 2.77M | 5.07M |
| Total Liabilities | 159.63M | 153.69M | 234.89M | 143.61M | 131.59M | 59.39M |
| Stockholders Equity | 41.33M | 53.83M | 143.88M | 259.59M | 343.39M | 161.30M |
Cash Flow | ||||||
| Free Cash Flow | -98.74M | -117.75M | -135.38M | -88.11M | 12.03M | -69.85M |
| Operating Cash Flow | -91.33M | -110.28M | -129.48M | -84.55M | 21.32M | -57.87M |
| Investing Cash Flow | -5.93M | 13.35M | 137.16M | -195.54M | 690.00K | 8.06M |
| Financing Cash Flow | -2.93M | -3.05M | 94.21M | 240.83M | -2.46M | -3.17M |
Ryvu Therapeutics SA Technical Analysis
Positive
27.65
Price Trends
15.58
Positive
18.13
Positive
21.88
Negative
Market Momentum
0.86
Negative
65.14
Neutral
67.10
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PL:RVU, the sentiment is Positive. The current price of 27.65 is above the 20-day moving average (MA) of 16.87, above the 50-day MA of 15.58, and above the 200-day MA of 21.88, indicating a neutral trend. The MACD of 0.86 indicates Negative momentum. The RSI at 65.14 is Neutral, neither overbought nor oversold. The STOCH value of 67.10 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PL:RVU.
Ryvu Therapeutics SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | zł127.36M | -2.22 | -95.68% | ― | -53.36% | -45.92% | |
40 Underperform | zł503.86M | -134.08 | -1.15% | ― | -1.63% | 26.23% | |
37 Underperform | zł427.72M | -4.70 | -135.46% | ― | -15.04% | 24.48% | |
34 Underperform | zł463.80M | -9.21 | -150.18% | ― | -82.90% | 2.18% |
* Healthcare Sector Average
PL:RVU
Ryvu Therapeutics SA
18.38
-10.82
-37.05%
PL:SVE
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.
3.02
-1.78
-37.08%
PL:CTX
Captor Therapeutics SA
71.10
30.10
73.41%
PL:MOC
OncoArendi Therapeutics SA
6.12
-1.65
-21.24%
PL:SLV
Selvita SA
26.95
-4.55
-14.44%
PL:MAB
Mabion SA
7.85
-1.45
-15.59%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.